Immunotherapy plus PARP inhibitor for HR-positive advanced breast cancer
Part of Cancer clinical trials.
This study tests a combination of an immunotherapy drug (adebrelimab) and a PARP inhibitor (fluzoparib) for people with HR-positive, HER2-negative breast cancer that has spread. It may help if your tumor has a specific genetic feature called HRD-positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your cancer is advanced (metastatic), hormone receptor-positive (HR+), and HER2-negative.
- Your tumor is HRD-positive (a type of genetic testing) — having a BRCA mutation is also okay.
- You can have had up to one line of chemotherapy for metastatic disease, but not more.
- You must have had at least one standard hormone therapy (including CDK4/6 inhibitor) — you may have had up to one antibody-drug conjugate (ADC).
- You have not been treated with PD-1/PD-L1 immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
This trial tests a drug called fluzoparib (a PARP inhibitor) after surgery for early breast cancer in people with specific gene mutations that affect DNA repair. The goal is to see if this drug lowers the chance of cancer coming back.
Hear when a new Female Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.